How many investments has Sofinnova Ventures made?

Sofinnova Ventures has 178 tracked investments, 11 of which have exited via acquisition or IPO, including 7 dated in the last 24 months.

What stage does Sofinnova Ventures invest at?

Sofinnova Ventures invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What is Sofinnova Ventures's typical check size?

Sofinnova Ventures typically writes checks of $100K – $15M.

What sectors does Sofinnova Ventures focus on?

Sofinnova Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is Sofinnova Ventures located?

Sofinnova Ventures is headquartered in Menlo Park, US.

Does Sofinnova Ventures lead rounds?

Sofinnova Ventures typically participates in rounds rather than leading them.

Who does Sofinnova Ventures co-invest with?

Sofinnova Ventures most often shares deals with Foresite Capital, New Enterprise Associates (NEA), RA Capital, among 107 tracked co-investors.

Sofinnova Ventures

Venture capitalActively deploying

Menlo Park · Seed–Late Stage · 47 people tracked

Also known as Sofinnova Investments, Inc. · Sofinnova Venture Partners

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Sofinnova concentrates on backing transformative biotech companies across their full lifecycle. The firm positions itself as a hands-on, experienced partner that supports founders from a company's inception through the stages of drug development, navigating the regulatory process, building the organization, and reaching a public offering. Its emphasis is on life sciences innovation, working collaboratively with entrepreneurs through every phase of growth.

Invests inBiotech Digital Health Healthtech Medical Devices Global Menlo Park North America United States

Source: firm website, verified Aug 27, 2026.

Stage

Seed–Late Stage

Check

$100K – $15M

Menlo Park, CA, US

Leads rounds

Follows

Instruments

Equity

Founded

1976

Last 12 months

9 investments

AUM

$5.4B

Tracked investments

211

Team · 47 people

from the firm's website & public directories

Eric Delbridge· General Partner, Public Equity

Eric Delbridge is a General Partner at Sofinnova Ventures, where he leads development of the firm's BioEquities strategy focused on public investments in global therapeutics companies. He joined Sofinnova in 2016 after managing market neutral therapeutics and healthcare portfolios at Balyasny Asset Management, and was previously a Partner at Spring Point Capital (formerly Botti Brown Asset Management) and a healthcare investment banker at Lazard and Credit Suisse. He holds an M.D. from Northwestern University, an M.B.A. from The Wharton School, and a B.A. in Classics from Yale University.

Maha Katabi· General Partner· Montrealin

Maha Katabi is a PhD in Pharmacology and CFA who built crossover public/private biotech investing platforms, focuses on clinical‑stage single‑asset radiopharmaceutical and targeted oncology companies, and chairs Exactis Innovation.

m•••@sofinnova.comreveal

Aneal Tenjarla· Partner, Associate Portfolio Manager, Public Equityin

Aneal Tenjarla is a Partner and Associate Portfolio Manager for Sofinnova BioEquities, concentrating on public investments in global biotechnology, pharmaceutical, and medical technology companies, with more than ten years in public healthcare investing. Before joining Sofinnova in 2019, he spent five years as a Senior Analyst at Citadel managing a healthcare-focused portfolio, and earlier worked as an Analyst at Point72 covering healthcare and as an investment banker at Greenhill focused on healthcare M&A. He holds an M.S. in Biotechnology from Johns Hopkins and a B.B.A. from the University of Texas at Austin.

Chris Carpenter· Executive Partner, Private Equityin

Chris Carpenter is an oncology physician-scientist with over two decades of clinical and laboratory experience who joined Sofinnova in 2022, focusing on clinical-stage product companies in oncology, rare diseases, and specialty therapeutics. He previously served as Chief Medical Officer at CatamaranBio and Rubius Therapeutics, and led cancer epigenetics at GlaxoSmithKline as well as drug development work at Merck. He holds a B.S. from Stanford University and M.D. and Ph.D. degrees from the University of Southern California, and is board certified in internal medicine and medical oncology.

c•••@sofinnova.comreveal

Hooman Shahlavi· Partner & Chief Legal Officerin

Hooman Shahlavi handles legal matters at Sofinnova, including the structuring, negotiation, and execution of initial and follow-on investments, restructurings, major corporate transactions, exits, and wind-downs, as well as compliance, fund formation, and risk and director liability issues. He joined the firm in 2007 after practicing as an attorney at O'Melveny & Myers (2003-2007) and Brobeck, Phleger & Harrison, where he worked on venture capital, M&A, and public offering transactions. He holds a J.D. from the University of California, Hastings College of Law and a B.S. in Business Administration from San Jose State University.

Jakob Dupont· Executive Partner, Private Equityin

Jakob Dupont is a physician with over two decades of experience in oncology and other therapeutic areas, focused on developing therapies for high unmet medical needs. Before joining Sofinnova in 2023, he held senior R&D and medical leadership roles at Atara Biotherapeutics, Gossamer Bio, Genentech/Roche, and OncoMed Pharmaceuticals. He earned his M.D. from Cornell University's Weill Medical College and an M.A. in philosophy from New York University, and completed his oncology fellowship at Memorial Sloan Kettering Cancer Center.

j•••@sofinnova.comreveal

Jim Healy· Managing Partner· Menlo Park, California

Jim Healy has spent about twenty years investing at Sofinnova, backing thirty-two companies in the biotechnology and healthcare space, many of which have gone public or been acquired. He holds a B.A. in Molecular Biology and a B.A. in Scandinavian Studies from UC Berkeley, and earned his MD and PhD in Immunology from Stanford University through the NIH Medical Scientist Training Program. Before Sofinnova, he worked at Bayer (Miles) and Sanderling, and has lectured on entrepreneurship at Stanford.

j•••@sofinnova.comreveal

Jonathan Leff· Executive Partner, Private Equity· Menlo Park, Californiain

Jonathan Leff is a physician with over 25 years of clinical development experience in the biotechnology and pharmaceutical industry, advising companies on drug development from target identification through market approval. Before joining Sofinnova in 2020, he was SVP and Chief Medical Officer of Ascendis Pharma, EVP of Research and Development at InterMune (where he led development and US approval of Esbriet for idiopathic pulmonary fibrosis), and held CMO roles at KaloBios Pharmaceuticals and Halozyme Therapeutics, plus positions at Roche, Amgen, and Merck. He holds a B.A. in Chemistry and an M.D. from the University of Pennsylvania, and completed training in Internal Medicine and Pulmonary and Critical Care Medicine at the University of Colorado, Denver.

j•••@sofinnova.comreveal

Lars Ekman· Executive Partner, Private Equity· San Diego, Californiain

Lars Ekman is a global R&D executive and drug developer with more than 30 years of experience across executive, scientific, and clinical roles, and he brings his life science background to the investment team. Before joining Sofinnova in 2008, he was President of Research and Development at Elan, having earlier held R&D leadership at Schwarz Pharma AG and various senior scientific and clinical roles at Pharmacia (now Pfizer). He earned his MD and PhD from the University of Gothenburg, Sweden, and is a board-certified surgeon with a PhD in Experimental Biology.

e•••@sofinnova.comreveal

Maha Radhakrishnan· Executive Partner, Private Equity

Maha Radhakrishnan is an industry executive with decades of experience in product development, commercialization, and global medical strategy across biotechnology and pharmaceutical companies. Before joining Sofinnova in 2024, she served as Consultant to the CEO at Dyne Therapeutics, Chief Medical Officer at Biogen, and Senior Vice President and Global Head of Medical for the Primary Care Business Unit at Sanofi, with earlier leadership roles at Bioverativ, Bristol Myers Squibb, United Health Group, and Cephalon. She holds an M.D. in internal medicine from the People's Friendship University in Moscow and a master's degree in Russian language.

Nathalie Auber· Partner & CFOin

Nathalie Auber has more than twenty years of private equity experience across financial reporting, operations, and deal structuring, and works with the investment team on financings, exit strategy, and valuations. She leads Sofinnova's Finance & Accounting team and administrative functions, having joined the firm in 1996. Earlier in her career she served as Director of Internal Audit at Catellus Development and spent seven years as an auditor with Deloitte and Touche in Paris and San Francisco.

a•••@sofinnova.comreveal

Sarah Bhagat· General Partner· Menlo Park, Californiain 𝕏

Sarah Bhagat, with a Ph.D. in Neuroscience from Yale and psychiatry postdoc at Stanford, is a hands-on, board-active partner focused on scientifically ambitious therapeutics like gene therapy, immuno-oncology and CNS conditions.

Regina Salvat· Principal· Cambridge, Massachusetts

Alex Chan· Controller, Private Equity

Alex Chan joined Sofinnova's Finance Department in 2013 as Senior Accountant and became Controller in 2021, handling the day-to-day accounting for the firm and its funds. Before Sofinnova, he worked at an international public accounting firm providing assurance and advisory services to public and private companies in the IT and biotech sectors. He holds a B.A. in Economics from UCLA and is a Certified Public Accountant in California.

Alex Dulnev· IT Managerin

Amanda Phillips· Executive Assistantin

Anastasia Voevodin· Analyst, Public Equity

Anastasia Voevodin joined Sofinnova BioEquities as an Analyst in 2024, where she focuses on public biotech investments. She previously worked as a Senior Research Associate at Avoro Capital covering public biotech, and as a management consultant at ZS Associates serving biotech clients. She holds a PhD in Chemistry from Columbia University and a BA in Chemistry with a Biomedical Engineering Science minor from Boston University.

Calvin Sternick· Analyst, Public Equity

Calvin Sternick joined Sofinnova BioEquities as an Analyst in 2026, working on public investments in healthcare services. He previously worked as an Analyst at Millennium Management covering areas such as contract research organizations, hospitals, laboratories, and managed care organizations, and served as Vice President of Managed Care & Facilities Equity Research at JPMorgan Chase. Earlier roles included healthcare equity research at TD Cowen and FBR Capital Markets and a structured finance valuation position at EY; he holds a B.S. in Accounting from Binghamton University.

David Kabakoff· Executive Advisor, Private Equity

David Kabakoff is a medicinal chemist with more than 30 years of experience leading technology and product development in the pharmaceutical, biopharmaceutical, and drug delivery fields. Before joining Sofinnova in 2007, he co-founded the cancer drug developer Salmedix, serving as Chairman and CEO until its acquisition by Cephalon, and previously held executive roles at Dura, Spiros Development, Corvas International, and Hybritech. He holds a PhD from Yale University and a BA from Case Western Reserve University.

d•••@sofinnova.comreveal

Debbie Murray· Chief People Officerin

Debbie Murray joined Sofinnova as Chief People Officer in 2020, where she leads strategic and operational initiatives tied to business performance goals. She previously served as Chief People Officer at BlueJeans Network and as Vice President at DataStax, Inc., where she oversaw human resources and business administration during the company's early growth. She holds a B.A. in Speech Communication from the University of San Diego.

Dina Hauser· Executive Assistantin

Eric Hsu· Analyst, Private Equityin

Eric Hsu joined Sofinnova as an Analyst in 2025, focusing on biopharmaceutical company investments across multiple disease areas and therapeutic modalities. He earned a PhD in Neuroscience from Johns Hopkins University, where his research in Dr. Dwight Bergles' lab used microscopy methods to study non-neuronal cell signaling in the brain and the effects of ketamine on that signaling. He previously held a BA in Neuroscience from Washington University in St. Louis and served as a Venture Fellow for Insight Partners and Sofinnova.

Gina Baker· Compliance & Operations Manager, Public Equity

Gina Baker joined Sofinnova in 2022 as a Compliance/Operations Manager, handling operations for Sofinnova BioEquities and helping oversee firm compliance. She previously served as Senior Finance Manager of the public equities division at Vista Equity Partners and has held compliance, finance, and operations roles at investment firms including SPO Partners and Apex Capital. She holds a B.S. in Business Administration with emphases in Accounting and Corporate Management from California State University, Hayward.

James Brody· Chief Compliance Officer & Chief Operating Officer, Public Equity

Jim Brody joined Sofinnova in 2016 as Chief Compliance Officer for the firm and Chief Operating Officer for Sofinnova BioEquities. He previously served as Chief Compliance Officer and Managing Director of Operations at Apex Capital, LLC, and held earlier roles at Pershing, Nollenberger Capital Partners, Wells Fargo Securities, and Robertson Stephens. He holds an M.B.A. from the University of San Francisco and a B.S. from the University of Oregon.

Jenn Symmons· Events Manager & Executive Assistantin

John Barrett· Senior Analyst, Public Equityin

John Barrett is a Senior Analyst at Sofinnova BioEquities, where he works on public biotech investments across all therapeutic areas. He previously worked as a biotech analyst at Parkman Healthcare Partners covering SMid cap therapeutic areas and at Leerink covering SMid cap oncology. He holds a Ph.D. in Molecular Engineering from the University of Chicago and a B.S. in Biomedical Engineering from Boston University.

Josie Kastelic· Menlo Park Office Manager & Executive Assistant· Menlo Park

Kasey Olson· Boston Office Manager & Executive Assistant· Boston

Kathy Du· Vice President of Finance, Public Equity

Kathy Du joined Sofinnova in 2025 as Vice President of Finance for the Public Equity team, overseeing the financial operations of Sofinnova Public Markets. She previously served as Chief Financial Officer at One01 Capital and held controller roles at Paradigm and Passport Capital. She earned a B.S. in Business Administration with an accounting emphasis from the University of California, Berkeley, and is an inactive Certified Public Accountant.

Katrin Viller· Vice President Finance, Private Equity

Katrin Viller joined Sofinnova as Vice President of Finance in 2024, where she oversees the financial aspects of Sofinnova Venture funds. She previously served as Head of Finance at Kleiner Perkins and held several roles at PricewaterhouseCoopers in Estonia and San Jose, including auditing asset management and life science clients. She holds a B.A. in International Business from Estonian Business School and is a Certified Public Accountant in California.

Laurel Russell· New York Office Manager & Executive Assistant· New Yorkin

Lesley Weber· Executive Assistant

Mike Van· Associate, Private Equityin

Mike Van joined Sofinnova as an Analyst in 2022 and became an Associate in 2024, where he focuses on biopharmaceutical companies and investments. He earned a PhD in Biology from Stanford University, working in Lacramiora Bintu's lab on CRISPR-based epigenome editing tools, and holds a BS in Biochemistry and Molecular Biology from UC Davis. During his time at Stanford he was a venture fellow at Sofinnova and consulted in roles at biotech companies including Maze Therapeutics, Octant, and Wearlinq.

v•••@sofinnova.comreveal

Naomi Pacalin· Associate, Private Equityin

Naomi Pacalin joined Sofinnova as an Analyst and became an Associate in 2025, where she works on biopharmaceutical company investments across multiple disease areas and therapeutic modalities. She holds a PhD in Bioengineering from Stanford University, where her research in Howard Chang's lab covered epigenomics and gene regulation using CRISPR epigenetic editing and single-cell sequencing. She also earned a BS in Biological Chemistry and a BA in Chemistry from the University of Chicago, and previously served as a Sofinnova Venture Fellow.

n•••@sofinnova.comreveal

Nick Lenard· Analyst, Public Equity

Nick Lenard joined Sofinnova BioEquities as an Analyst in 2025, where he works on public investments in biotechnology and pharmaceutical companies globally. He previously spent over four years on the sell side covering SMid and Large Cap Biotechnology, most recently as a Vice President at J.P. Morgan. He holds an M.A. in Biotechnology from Columbia University and a B.A. in Chemistry from Kenyon College.

Paul Chang· Analyst, Public Equityin

Paul Chang is an Analyst who joined Sofinnova BioEquities in 2025, where he works on public investments in medical technology and diagnostics. He previously served as an Investment Associate at TPG Growth, sourcing healthcare investments and supporting portfolio companies, and before that was an investment banker at Goldman Sachs covering healthcare M&A and financing. He holds a BS in Finance with a minor in English Literature from New York University.

Perry Nisen· Executive Advisor, Private Equity· San Diego, Californiain

Perry Nisen is a physician scientist with experience in drug discovery and development, focusing on pre-clinical and clinical companies in oncology, neuroscience, and immunology/inflammation. He joined Sofinnova in 2018 and previously served as CEO of the Sanford Burnham Prebys Medical Discovery Institute and held senior roles at GlaxoSmithKline, including SVP of Science and Innovation, interim Chief Medical Officer, and Oncology Therapy Area Head, as well as a cancer research leadership role at Abbott Laboratories. He earned a BS from Stanford University and an MD/PhD from the Albert Einstein College of Medicine.

p•••@sofinnova.comreveal

Rachel Urrutia· Finance and HR Coordinatorin

Raymond Bower· Portfolio Manager, Synergy Fundin

Ray Bower joined Sofinnova in 2022 as Portfolio Manager of the Synergy Fund, concentrating on biotechnology and therapeutics. His earlier career included work as a medical director of a primary care clinic and in biologic product strategy at Centocor, followed by sell-side work at Citigroup, a partner and analyst role covering healthcare at Lee Munder Capital Group in Boston, running a biotech portfolio at TIAA CREF, and serving as Principal at Adenium Research. He holds a Bachelor of Medical Science and an M.D. from the University of Alberta and an MBA from the Wharton School at the University of Pennsylvania.

Seth Filbrun· Associate, Public Equityin

Seth Filbrun joined Sofinnova as an Associate in 2026 with Sofinnova BioEquities, where he works on public biotech investments. He previously worked as an Equity Research Associate at Stifel Financial covering small- and mid-cap biotech companies in immunology & inflammation and endocrinology, and before that as a Senior Consultant at Simon Kucher. He holds a Ph.D. in Analytical Chemistry from Georgia State University, an M.S. in Chemistry from Illinois State University, and a B.S. in Chemistry from Miami University.

Smita Chowdhri· Controller, Public Equityin

Smita Chowdhri joined Sofinnova BioEquities as a Controller in 2026, handling accounting and finance for the public equity team. She previously served as Controller at Intrinsic Edge Capital Management and held roles at Gen II Fund Services, Jump Trading, Jump Capital, Wolverine Asset Management, and Navigant Consulting, where her work spanned fund accounting, investor reporting, regulatory compliance, and forensic accounting. She holds a Bachelor of Science in Finance, Accounting, and Business Process Management from Indiana University and is a CPA in Illinois.

Steve Bilawey· IR and Marketing, Public Equity

Surin Kim· Financial Analyst, Private Equity· San Francisco, California

Surin Kim joined Sofinnova in 2021 as a Financial Analyst, handling fund accounting and tax matters. He previously worked as a Tax Senior at BDO USA, LLP, focusing on tax issues related to alternative investments, and earlier served as a private banker at Mirae Asset Securities (Daewoo Securities) in South Korea. He holds a Master of Science in Taxation from Golden Gate University and a Bachelor's degree in Business Administration from Inha University.

Tiffany Davis· Director of IR and Marketing, Private Equity

Troy Ignelski· Executive Advisor, Private Equity

Troy Ignelzi· Executive Advisor, Private Equity

Leighanne Oh· Analyst· New York, New Yorkin

What they invest in

from 112 of 211 portfolio companies

Biotech ×103Healthtech ×48Medical Devices ×37Digital Health ×9Deep Tech ×7AI & Machine Learning ×3Hardware ×2Longevity ×2

HQs:United States×89Denmark×2France×2United Kingdom×1Netherlands×1Norway×1

Who they back

founder profiles across 28 portfolio companies

57%

solo founders

16 of 28 mapped founding teams

~5 yrs

old at investment

median across 14 dated deals

Founding team size:solo founder×162 founders×73 founders×34+ founders×2

Investments · 211 tracked

founders shown can be your intro path

By year:2026 · 5 2025 · 6 2024 · 6 2023 · 3 2022 · 2 2021 · 6 2020 · 1 2019 · 1 2018 · 2 2017 · 2 2016 · 2 2015 · 344 dated

BioAge Labsbioagelabs.com in 𝕏NASDAQ: BIOAFeb 2024

BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.

BiotechHealthtechLongevityRichmond, US

Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Kristen Fortney(Executive Officer, Director)inEric Morgen(Director)Dov Goldstein(Executive Officer)

BoardPatrick Enright(Director)in

Board seatJames Healy· per SEC Form D

Co-investorsAndreessen Horowitz Elad Gil Felicis Ventures IA Seed Ventures Longitude Capital OrbiMed +2 more

NextCurenextcure.comNASDAQ: NXTCDec 2025

Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.

BiotechBeltsville, US

Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)Udayan Guha(Executive Officer)Steven P. Cobourn(Executive Officer)Sourav Kundu(Executive Officer)Kevin Shaw(Executive Officer)

Board seatDavid Kabakoff· per SEC Form D

Co-investorsBay City Capital Canaan Partners LAV Lilly Asia Ventures Pfizer Venture Investments Quan Capital +2 more

Seaport Therapeuticsseaporttx.com in 𝕏NASDAQ: SPTXOct 2024

Seaport Therapeutics develops therapeutics and medicines.

BiotechMental HealthBoston, US

Daphne Zohar(Founder, CEO and Board Member)inMichael Chen(Executive Officer)Lana Gladstein(Executive Officer)Antony Loebel(Executive Officer)Eric Green(Executive Officer)

Board seatJames I. Healy· per SEC Form D

Co-investorsARCH Venture Partners Foresite Capital HAWKTAIL PureTech Health

Vera TherapeuticsNASDAQ: VERAFeb 2021

Developing innovative biologic therapeutics with transformative clinical potential.

South San Francisco, US

Board seatMaha Katabi· per SEC Form D

Co-investorsAbingworth Kleiner Perkins

Aclaris Therapeuticsaclaristx.comNASDAQ: ACRS

Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.

BiotechHealthtechMedical DevicesWayne, US

Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)Stuart D. Shanler(Executive Officer)Joseph Monahan(Executive Officer)Hugh Davis(Executive Officer, Director)James Loerop(Executive Officer)

Co-investorsAisling Capital APERTURE Venture Partners F-Prime Capital Foresite Capital RA Capital Sofinnova Venture Partners +1 more

Anavex Life Sciencesanavex.com in 𝕏NASDAQ: AVXL

Anavex Life Sciences is a clinical-stage biopharmaceutical company developing oral therapeutics for central nervous system disorders, including Alzheimer's disease, Rett syndrome, and Fragile X syndrome.

BiotechHealthtechPortola Valley, US

Alexandre Vamvakides(Executive Officer)Axel Paeger(Board Member (founder))Harvey Lalach(Executive Officer, Director)George Tidmarsh(Executive Officer, Director)Terrie Kellmeyer(Interim Chief Executive Officer)Christopher U. Missling(Executive)

aTYR PHARMAatyrpharma.com 𝕏NASDAQ: ATYR

aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.

BiotechHealthtechMedical DevicesSan Diego, US

Paul Schimmel(Non-Management Director)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)Frederic Chereau(Executive Officer)

BoardAmir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)

Co-investorsCardinal Partners EcoR1 Capital Domain Partners Polaris Partners Samsara BioCapital

Bolt Biotherapeuticsboltbio.com in 𝕏NASDAQ: BOLT

Bolt Biotherapeutics develops cancer immunotherapies that use the innate immune system to help the body recognize and eliminate tumor cells.

Co-investorsPfizer Venture Investments RA Capital Samsara BioCapital Vivo Capital Nan Fung Life Sciences Novo Holdings +1 more

Coherus Biosciencescoherus.com in 𝕏NASDAQ: CHRS

Coherus Oncology develops and commercializes immuno-oncology therapies, including the approved LOQTORZI, to treat patients with cancer.

BiotechHealthtechMedical DevicesRedwood City, US

Dennis M. Lanfear(Executive Officer, Director)Denny Lanfear(Founder)inAlan C. Herman(Executive Officer)Jean-Frederic Viret, Ph.D.(Executive Officer)Peter K. Watler, Ph.D.(Executive Officer)Barbara K Finck, M.D.(Executive Officer)

Co-investorsF-Prime Capital HEALTHCARE ROYALTY PARTNERS Venrock

Editas Medicineeditasmedicine.com in 𝕏NASDAQ: EDIT

Editas Medicine develops gene-editing medicines using CRISPR technology to treat serious genetic diseases.

BiotechMedical DevicesCambridge, US

Katrine Bosley(Executive Officer, Director)inVic Myer(Executive Officer)Alexandra Glucksmann(Executive Officer)Douglas Cole(Director)Kevin Bitterman(Director)Andrew Hack(Executive Officer)

Co-investorsEcoR1 Capital

Enanta Pharmaceuticalsenanta.com in 𝕏NASDAQ: ENTA

Enanta Pharmaceuticals is a biotechnology company that discovers and develops small-molecule therapeutics using chemistry-based research to treat diseases with high unmet medical need.

Biotech

Kiniksa PharmaceuticalsNASDAQ: KNSA

Clinical-stage biopharma developing therapies for debilitating diseases with unmet need.

BiotechHamilton

RICHARD S LEVY(Director)STEPHEN R BIGGAR(Director)FELIX J BAKER(Director)THOMAS W BEETHAM(Executive Officer)SANJ K PATEL(Executive Officer, Director)THOMAS R MALLEY(Director)

Ligand PharmaceuticalsNASDAQ: LGNDJan 2016

BiotechLa Jolla, US

Brook Byers(Co-founder)inMATTHEW W. FOEHR(Director)JOHN L. HIGGINS(Executive Officer, Director)MATTHEW KORENBERG(Director)CHARLES S. BERKMAN(Director)

BoardDAVID M. KNOTT(Director)

Co-investorsVenrock

Nateranatera.com in 𝕏NASDAQ: NTRA

Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.

BiotechDigital HealthHealthtechMedical Devices

Matthew Rabinowitz(Co-founder & Executive Chairman)Jonathan Sheena(Founder)in

Co-investorsBain Capital Life Sciences Cheyenne Ventures Claremont Creek Ventures Foresite Capital Harmony Partners Lightspeed Venture Partners +1 more

Nucananucana.comNASDAQ: NCNA

Hugh Griffith(Founder)in

Protalix BioTherapeuticsNYSE: PLX

Prothenaprothena.com in 𝕏NASDAQ: PRTAMar 2018

Prothena is a clinical-stage biotechnology company developing investigational therapies for neurodegenerative and rare peripheral amyloid diseases by targeting misfolded proteins.

BiotechDun Laoghaire, Co. Dublin, US

Tran B. Nguyen(Executive Officer)Arthur W. Homan(Executive Officer)Karin L. Walker(Executive Officer)Tara Nickerson, Ph.D.(Executive Officer)Wagner M. Zago, Ph.D.(Executive Officer)Carol D. Karp(Executive Officer)

Rapport Therapeuticsrapportrx.com inNASDAQ: RAPP

Rapport is a biopharmaceutical company developing novel therapeutics.

BiotechHealthtechMedical Devices

Abe Ceesay(President)Cheryl GaultDr. Sevigny

Co-investorsARCH Venture Partners

Seres Therapeuticsserestherapeutics.com in 𝕏NASDAQ: MCRB

Seres Therapeutics is a clinical-stage biotechnology company developing therapies composed of rationally selected live bacterial consortia to treat serious diseases through modulation of the human microbiome.

BiotechDigital HealthHealthtechMedical DevicesCambridge, US

Matthew Henn(President and Chief Scientific Officer)

Co-investorsFlagship Pioneering RA Capital

Syndax Pharmaceuticals inNASDAQ: SNDX

BiotechWaltham, US

John Pallies(Executive Officer)Arlene Morris(Executive Officer, Director)

BoardDennis Podlesak(Director)Ivor Royston(Director)Luke Evnin, Ph.D.(Director)Kim Kamdar, Ph.D(Director)

Co-investorsForesite Capital Pappas Capital venBio Partners

Synlogicsynlogictx.com in 𝕏OTC: SYBX

Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.

BiotechDeep TechMedical DevicesCambridge, US

Bharatt Chowrira(Executive Officer)Michael Sheahan(Executive Officer)Jose Carlos Gutierrez-Ramos(Executive Officer, Director)Paul Miller(Executive Officer)Aoife Brennan(Executive Officer)Todd Shegog(Executive Officer)

Co-investorsAtlas Venture New Enterprise Associates (NEA)NSG Ventures Pfizer Venture Investments Solasta Ventures OrbiMed

Alediaaledia.com in✓ verified

Aledia develops next-generation MicroLED display technology based on 3D nanowires grown on silicon, operating a pilot line and high-volume production facility.

Deep TechHardwareSemiconductorsGrenoble, FR

philippe GILET(Founder)in

Co-investorsBraemar Energy Ventures Intel Capital Demeter Ingka Investments Supernova TEL Venture Capital, Inc.+3 more

Axonis Therapeuticsaxonis.us inOct 2024✓ verified

Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.

BiotechDeep TechBoston, US

Shane Hegarty(Executive Officer)Shane V. Hegarty(Chief Scientific Officer & Co-Founder)Jeffrey Imbaro(Executive Officer)Joanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)Tiasha Shafiq(Chief of Staff)

Co-investorsvenBio Partners MRL Ventures Fund Civilization Ventures Management, Llc Creative Destruction Lab (CDL)Hatteras Venture Partners Iaso Ventures +7 more

Expeditiontxexpeditiontx.com in✓ verified

Expedition Therapeutics develops oral small-molecule treatments for inflammatory and respiratory diseases, with lead candidate EXPD-101, a once-daily DPP1 inhibitor for chronic obstructive pulmonary disease (COPD).

BiotechHealthtechSan Francisco, US

Co-investorsForbion Novo Holdings Sanofi Ventures

Adaptive Phage TherapeuticsJun 2023SEC filingmedium confidence

BiotechGaithersburg, US

Gregory L. Merril(Executive Officer, Director, Promoter)Carl R. Merril(Executive Officer, Director)

BoardEvan Loh(Director)Jana Jensen(Director)Raymond L. Martz(Director)

Board seatJonathan Leff· per SEC Form D · $30M raise · filed Jun 2023

Co-investorsAMR Action Fund

Aeovian Pharmaceuticalsaeovian.comDec 2025

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.

BiotechBerkeley, US

Allison J. Hulme(CEO & President)John Kincaid(Chief Scientific Officer)Davis Ryman(Executive Officer)Micah Zajic(Executive Officer)Ian Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)

Board seatLars Ekman· per SEC Form D

Co-investorsCoastCap CTI Life Sciences Fund L.P.FJ Labs venBio Partners venBio Global Strategic

Aerovate Therapeutics, Inc.Aug 2020

Developing drugs for rare cardiopulmonary disease.

Boston, US

Board seatMaha KatabiJonathan Leff· per SEC Form D

Co-investorsAtlas Venture

Antiva Biosciencesantivabio.com inNov 2021 · $53M

Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.

BiotechFemTechHealthtechMedical DevicesRedwood City, US

Karl Y. Hostetler(Executive Officer, Director)Gail Maderis(Director)Kristine Ball(Executive Officer, Director)Elaine Chien(Executive Officer)Sarah Walter(Executive Officer)Raju Gadiraju(Executive Officer)

Board seatDavid Kabakoff· per SEC Form D

Co-investorsAdjuvant Capital Brace Pharma Canaan Partners Lumira Ventures MPM BioImpact OUP (Osage University Partners)+3 more

Apellis Pharmaceuticals, Inc.Aug 2017

Developing therapeutics for autoimmune and inflammatory diseases.

Crestwood, US

Board seatMaha Katabi· per SEC Form D

Arriventarrivent.com inDec 2022

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.

BiotechHealthtechMedical DevicesNewtown Square, US

Zhengbin (Bing) Yao(Executive Officer, Director)Brent Rice(Chief Commercial Officer)

BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)

Board seatJames Healy· per SEC Form D

Co-investorsCatalio Capital Management, LP Foresite Capital General Catalyst HongShan Capital Group LAV Lilly Asia Ventures +2 more

Atsena Therapeutics, Inc.Apr 2025SEC filingmedium confidence

Durham, US

Board seatChris CarpenterJames Healy· per SEC Form D · $150M raise · filed Apr 2025

Bolt TherapeuticsJun 2021

Pleasanton, US

Chih-Ping Liu(Executive Officer, Director, Promoter)

BoardEdgar G Engleman(Director)

Board seatJames Healy· per SEC Form D

Co-investorsVivo Capital

Cleveland DiagnosticsOct 2025SEC filingmedium confidence

BiotechCleveland, US

Arnon Chait(Executive Officer, Director)ANDREW SUMMERS(Executive Officer)

BoardJOSEPH RICH(Director)SAMEER ROHATGI(Director)DARA WRIGHT(Director)

Board seatNoel Jee· per SEC Form D · $14.4M raise · filed Oct 2025

Co-investorsJobsOhio Ventures Jumpstart Ventures LYFE Capital

Effector Therapeuticseffector.comDec 2015SEC filingmedium confidence

eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.

BiotechSolana Beach, US

Stephen F. Worland, Ph.D.(Executive Officer, Director)Alana McNulty(Executive Officer)

BoardSimeon George(Director)Jonathan Root(Director)inKen Haas(Director)Laurence Lasky(Director)

Board seatMaha Katabi· per SEC Form D · $56M raise · filed Feb 2016

Co-investorsAstellas Venture Management LLC Mission Bay Capital Mission Biocapital OUP (Osage University Partners)Pfizer Venture Investments US Venture Partners

Elektrofi, Inc.Aug 2024SEC filingmedium confidence

Boston, US

Board seatNoel Jee· per SEC Form D · $112.3M raise · filed Oct 2024

Co-investorsSR One Capital Management

Genoa Pharmaceuticalsgenoa-pharmaceuticals.appspot.comOct 2023SEC filingmedium confidence

Avalyn Pharma (formerly Genoa Pharmaceuticals) is a biopharma company developing inhaled therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases.

BiotechHealthtechSan Diego, US

Mark W. Surber, Ph.D.(Executive Officer, Director)Richard G. Vincent(Executive Officer)

BoardMichael J. Kamdar(Director)Daniel D. Burgess(Director)

Board seatJonathan Leff· per SEC Form D · $189.2M raise · filed Oct 2023

Co-investorsNorwest Venture Partners RiverVest Venture Partners

Gyroscope Therapeutics LtdApr 2021SEC filingmedium confidence

BiotechStevenage, Hertfordshire

Ian Pitfield(Executive Officer)David Fellows(Director)Jessica Stitt(Executive Officer)Renee Gala(Director)Khurem Farooq(Executive Officer)Edward Lang(Executive Officer)

Board seatMaha Katabi· per SEC Form D · $148M raise · filed Apr 2021

Co-investorsForbion

Marea Therapeutics, Inc.Jun 2024SEC filingmedium confidence

San Francisco, US

Board seatMaha Katabi· per SEC Form D · $160.4M raise · filed Jun 2024

Co-investorsvenBio Partners

Quanta Therapeuticsquantatx.comJun 2026 · $50M

Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers.

BiotechDeep TechHealthtechSouth San Francisco, US

Cameron Pitt(Executive Officer, Director)Ying Huang(Director)Derek Metzger(Executive Officer)

BoardPerry Nisen(Executive Officer, Director)Maria Fardis(Director)

Board seatMaha Katabi· per SEC Form D

Co-investorsLongitude Capital Vida Ventures Biotechnology Value Fund Frazier Life Sciences

Rarecyterarecyte.comJul 2023SEC filingmedium confidence

Seattle, US

Ronald Seubert(Executive Officer, Director, Promoter)Evan Castiglia(Executive Officer)Joseph Victor(Executive Officer, Director)Frank Witney(Director)Eric Kaldjian(Executive Officer)

BoardRobert Shepler(Director)in

Board seatDavid Kabakoff· per SEC Form D · $35.7M raise · filed Jul 2023

Co-investors5AM Ventures Arboretum Ventures F-Prime Capital Telegraph Hill Partners

Rayze Biorayzebio.com inSep 2022

RayzeBio develops radiopharmaceutical therapies for cancer treatment.

BiotechHealthtechMedical DevicesSan Diego, US

Ken Song(Executive Officer, Director)Ben Hickey(President)Abhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)

BoardAaron Royston(Director)in

Board seatMaha Katabi· per SEC Form D

Co-investorsSamsara BioCapital Scion Life Sciences TCG Crossover venBio Partners Versant Ventures Vivo Capital +1 more

Route 92 Medicalr92m.com in 𝕏Jan 2026SEC filingmedium confidence

Route 92 Medical develops neurointervention catheter systems and devices aimed at improving outcomes for neurovascular patients, including stroke treatment.

BiotechHardwareHealthtechMedical DevicesSan Mateo, US

Dr. Chou(Founder & Chief Executive Officer)Cindy Lynch(Executive Officer)Tony Chou(Executive Officer, Director)in

BoardJack Lasersohn(Director)inTamir Meiri(Director)Jonathan Root(Director)in

Board seatNoel Jee· per SEC Form D · $50M raise · filed Apr 2026

Co-investorsNorwest Venture Partners Runway Growth Capital US Venture Partners The Vertical Group

Star Therapeuticsstar-therapeutics.comOct 2025

Star Therapeutics develops treatments aimed at addressing real-world patient needs.

BiotechSouth San Francisco, US

Adam Rosenthal(Founder & CEO)Jason Hafler(Director)Nancy Stagliano(Director)Michelle Carpenter(Executive Officer)Matthew Fust(Director)Amrit Nagpal(Director)

Board seatMaha Katabi· per SEC Form D

Co-investorsFrazier Life Sciences OrbiMed RA Capital Sanofi Ventures Agent Capital Blue Owl Capital +8 more

Acceleronacceleronpharma.com in 𝕏

A pharmaceutical company that develops medicines and vaccines for patients globally.

BiotechHealthtechMedical DevicesCambridge, US

WYLIE W. VALE(Director)JOHN KNOPF(Executive Officer, Director)STEVEN ERTEL(Executive Officer)ROBERT STEININGER(Executive Officer)KEVIN F. MCLAUGHLIN(Executive Officer)MATTHEW L. SHERMAN(Executive Officer)

Co-investorsBessemer Venture Partners Foresite Capital Lightstone Ventures Lowercarbon Capital Venrock Collaborative Fund

Achaogen

Co-investors5AM Ventures Frazier Life Sciences

Acrotech Pharmaceuticals

Actelionactelion.com

Actimis Pharmaceuticals

Focused on developing drugs, including for NASH and metabolic/inflammatory/fibrotic diseases.

Adeona Biotech

Advanced Oxygen Therapeutics

Aeriepharmaaeriepharma.com in

Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.

BiotechHealthtechMedical DevicesBedminster, US

DAVID GRYSKA(Director)VICENTE ANIDO(Executive Officer, Director)MURRAY GOLDBERG(Director)ANAND MEHRA(Director)BRIAN LEVY(Executive Officer)GERALD CAGLE(Director)

Co-investorsAlta Partners Avoro Capital Advisors Foresite Capital OUP (Osage University Partners)

Aerovatetxaerovatetx.com inacquired by Jade Biosciences

BiotechHealthtech

Aerpio Therapeuticsaerpio.com

BiotechCincinnati, US

Joseph H. Gardner(Executive Officer)Robert Shalwitz(Executive Officer)Joseph Gardner(Founder)inDuane Nash(Director)Kevin Peters(Executive Officer)Steve Pakola(Executive Officer)

Co-investorsCincyTech OrbiMed

Afyxtxafyxtx.com

AFYX is a biopharmaceutical company focused on reformulation and repurposing of existing pharmaceuticals for conditions including head and neck cancer, labor induction, cluster headaches, and pain and addiction.

BiotechHealthtechMedical DevicesHørsholm, DK

Dr. Claus J. Møller-San Pedro(CEO)

Aiolos Bioaiolosbio.com in 𝕏

Aiolos Bio is a biopharma company that discovers, develops, and delivers medicines and vaccines across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases.

BiotechHealthtech

Co-investorsBain Capital Life Sciences RA Capital

Akouosakouos.com in

Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.

BiotechHealthtechBrookline, US

Emmanuel Simons(Executive Officer, Director)william sewell(Founder)in

BoardEd Mathers(Director)inKush Parmar(Director)in

Co-investors5AM Ventures EcoR1 Capital New Enterprise Associates (NEA)RA Capital Cowen Healthcare Investments Fidelity Investments +1 more

Alimera Sciences

Alimerasciencesalimerasciences.com inacquired by ANI Pharmaceuticals

BiotechHealthtechMedical Devices

Co-investorsNew Enterprise Associates (NEA)

Alkeuspharmaalkeuspharma.com in 𝕏

Alkeus Pharma develops therapies for retinal diseases, including inherited and neovascular conditions.

BiotechDigital HealthHealthtechMedical DevicesCambridge, US

Carlos Quezada-Ruiz(Chief Medical Officer)

Co-investorsBain Capital Life Sciences TCG Crossover

Alvinepharmaalvinepharma.com 𝕏

Amarantus Bioscience

Amarinamarincorp.com in 𝕏

Amarin Corporation is a cardiovascular health pharmaceutical company developing treatments to prevent cardiovascular disease.

BiotechHealthtechMedical Devices

Co-investorsAvoro Capital Advisors Fountain Healthcare Partners Longitude Capital Signet Healthcare Partners

Amplyxamplyx.com

Co-investorsBioBrit Keiretsu Forum

Amplyx Pharmaceuticals

Developing broad-spectrum antifungal agents for invasive fungal infections.

BiotechSan Diego, US

Mitchell Mutz(Executive Officer, Director)

BoardChrysa Mineo(Director)Jack Florio(Director)Elaine Heron(Director)Santosh Vetticaden(Director)Karen Talmadge(Director)

Co-investorsNew Enterprise Associates (NEA)Pappas Capital RiverVest Venture Partners Sofinnova Venture Partners

Anesivaanesiva.com

Anesiva is a biopharmaceutical company developing Nexletol for diet management.

Biotech

Antheraanthera.com

Anthera produces makeup and skincare products made in France with natural, non-toxic ingredients that are cruelty-free and vegan.

ConsumerWellness & FitnessFrance, FR

Co-investorsVantagePoint Capital Partners

Anthera Pharma

Anthera Pharmaceuticals

Developing products for diseases associated with inflammation.

BiotechHayward, US

May Liu(Executive Officer)

Co-investorsPappas Capital

AntheriX Therapeutics

Apeiron Therapeuticsapeiron-bio.com in

Apeiron Therapeutics is a biotech company developing small-molecule therapeutics with a focus on immuno-oncology and oncology drug discovery.

AI & Machine LearningBiotechDeep TechHealthtechBurlingame, US

Mingxi Li(CEO)Fred Aswad(Chief Scientific Officer)

Co-investorsPanacea Venture

Apellisapellis.com in 𝕏

Co-investorsAvoro Capital Advisors Epidarex Capital F-Prime Capital Keyhorse Capital Solasta Ventures venBio Partners

Apollo Health Venturesapollo.vc in 𝕏Jan 2026

Apollo is a venture capital firm that invests in life-science and biotechnology startups, combining entrepreneurial expertise with deep scientific knowledge to support early-stage companies in drug development and personalized medicine.

BiotechDeep TechHealthtechLongevity

Nils Regge(Co-Founder & General Partner)in

Co-investorsBLN Capital CoastCap FJ Labs KfW Capital TruVenturo GmbH CTI Life Sciences Fund L.P.+3 more

Apolloheal

Appulse Corporation

Aralez PharmaceuticalsFeb 2016

BiotechVancouver

Andrew I. Koven(Executive Officer)Eric L. Trachtenberg(Executive Officer)Scott J. Charles(Executive Officer)Kenneth B. Lee Jr.(Director)Arthur S. Kirsch(Director)Adrian Adams(Executive Officer, Director)

Arcus Biosciencesarcusbio.com in 𝕏

Arcus Biosciences develops combination cancer therapies, producing small molecules and antibodies designed to be combined and advanced from Phase 1 studies through commercialization.

Biotech

Juan Jaen(Founder)in

Co-investorsAisling Capital Decheng Capital Droia Ventures EcoR1 Capital Foresite Capital SLVC +2 more

Ascendis Pharmaascendispharma.com in 𝕏Nov 2014

Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.

BiotechHealthtechMedical DevicesDenmark, DK

Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)James Healy(Director)Grethe Rasmussen(Executive Officer)Harald Rau(Executive Officer)Rafa?le Tordjman(Director)Martin Olin(Director)

Co-investorsVivo Capital Aisling Capital Avoro Capital Advisors Foresite Capital RA Capital

Asyndetan Holdings

Athena TherapeuticsMar 2021

BiotechWestport, US

Ranjit Bidra(Manager)

Athiraathira.com

A biotechnology company developing new therapies for patients with high unmet medical needs.

Biotech

Co-investorsDolby Family Ventures

Athira Pharma

Advancing therapies for neurodegenerative diseases like Alzheimer's and Parkinson's.

Atsenatxatsenatx.com in

Atsena Therapeutics is a clinical-stage gene therapy company developing treatments for inherited retinal diseases.

BiotechMedical Devices

Co-investorsLightstone Ventures Hatteras Venture Partners

Audentestxaudentestx.com

Co-investorsAisling Capital

Auris Pharmaceuticals

Aurismedicalaurismedical.com

Co-investorsKurma Partners

Avenzoavenzotx.com in

Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.

Biotech

Athena Countouriotis(Co-Founder, Chief Executive Officer)

Co-investorsDelos Capital Foresite Capital INCE Capital Longwood Fund New Enterprise Associates (NEA)OrbiMed +3 more

AveXis

New gene therapy treatments for people with serious, rare diseases.

BiotechBannockburn, US

James L'Italien(Executive Officer)Andrew F. Knudten(Executive Officer)Paul Manning(Director)Sukumar Nagendran(Executive Officer)Bong Koh(Director)Thomas Dee(Executive Officer)

Co-investorsForesite Capital PBM Capital RA Capital

BioDelivery Sciences

Capstan Therapeuticscapstantx.com in 𝕏

AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.

BiotechHealthtechMedical DevicesSan Diego, US

Adrian Bot(Executive Officer)Laura Shawver(Executive Officer, Director)Ramin Farzaneh-Far(Executive Officer)Justin Thacker(Executive Officer)Karen Smith(Director)Fabio Pucci(Director)

Co-investorsPfizer Venture Investments RA Capital Vida Ventures

Catalystbiosciencescatalystbiosciences.com

Co-investorsAvoro Capital Advisors New Enterprise Associates (NEA)

CaveoGel

Chameleon Pharma

Checkmate Pharmaceuticals

Activating the immune system to recognize and destroy tumor cells.

BiotechCambridge, US

Art Krieg(Executive Officer, Director)Barry Labinger(Executive Officer, Director)Chuck Abdalian(Executive Officer)David Mauro(Executive Officer)Karen Brennan(Executive Officer)Charles Yon(Executive Officer)

Co-investorsF-Prime Capital Longitude Capital Novo Holdings

Checkmatepharmacheckmatepharma.com

Co-investorsLongitude Capital

Chiasmachiasmapharma.com

BiotechNewton Centre, US

Chaime Orlev(Executive Officer)Roni Mamluk(Executive Officer, Director)

BoardScott Minick(Director)Todd T. Foley(Director)inVincent Miles(Director)Ansbert K. Gadicke(Director)in

Co-investorsHEALTHCARE ROYALTY PARTNERS MPM BioImpact

Chimera Therapeutics

CinCorcincor.com

Co-investors5AM Ventures

CinCor PharmaSep 2021

Advancing clinical candidates for cardiovascular, metabolic and kidney diseases.

BiotechCincinnati, US

Marc de Garidel(Executive Officer, Director)

Co-investorsSofinnova Partners

City Therapeuticscitytx.com in 𝕏

City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.

BiotechMedical DevicesCambridge, US

Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)

Co-investorsAN Venture Partners ARCH Venture Partners Casdin Capital Fidelity Investments Invus Rock Springs Capital

Civitas Therapeuticscivitastherapeutics.comAug 2014

BiotechChelsea, US

RICHARD BATYCKY(Executive Officer)GLENN BATCHELDER(Director)BRYAN STUART(Executive Officer)MARK IWICKI(Executive Officer, Director)MARTIN FREED(Executive Officer)

BoardROB HOPFNER(Director)

Co-investorsCanaan Partners Bay City Capital Longitude Capital OrbiMed RA Capital

Claris Bioclarisbio.com in

Claris Bio is a late-stage therapeutics company developing pharmacologic treatments for sight-threatening ophthalmic conditions with no or limited treatment options.

BiotechHealthtech

Co-investorsRA Capital Novo Holdings

Claris Biotherapeutics

BiotechJersey City, US

Henry Rath(Executive Officer)Susan Orr(Executive Officer)Clarke Atwell(Executive Officer, Director)Stephen Brady(Executive Officer, Director)Michael Dybbs(Director)Matt Hobson(Director)

Co-investorsCatalio Capital Management Novo Holdings Samsara BioCapital

Compugen Therapeutics

CoTherix

Received FDA approval for Tracleer to treat pulmonary arterial hypertension.

Co-investorsAlta Partners Frazier Life Sciences

Coultreoncoultreon.com inApr 2026 · $125M

Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.

AI & Machine LearningBiotech

Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)Marie De Vulder(Chief Legal Officer Co-founder)Guy Peeters(Chief Financial Officer Co-founder)John-Paul Gallivan(Head of Development Co-founder)Fabrice Kolb(Head of Immunology Co-founder)Pieter Peeters(Operating & Technology Officer Co-founder)

Co-investorsLongwood Fund BAM Elevate Finchley Healthcare Ventures Forbion Luma Group Novo Holdings +1 more

Dauntlessphdauntlessph.com

DealFormadealforma.com in 𝕏May 2024

DealForma is a curated biopharma deals database offering licensing deal comps, M&A data, company and drug pipeline profiles, funding rounds, and Tableau-based interactive dashboards with natural-language search.

BiotechData & InfrastructureHealthtech

Co-investorsTinySeed Alger RA Capital REDMILE RTW Investments L.P.

Ear Pharmaceuticals

Edge TherapeuticsApr 2015

Hospital-based therapies for acute, life-threatening neurological conditions.

BiotechBerkeley Heights, US

Robert Loch Macdonald(Executive Officer, Director)Brian A. Leuthner(Executive Officer, Director)Andrew Einhorn(Executive Officer)Albert N. Marchio II(Executive Officer)Herbert J. Faleck(Executive Officer)

BoardIsaac Blech(Director)

Edgetherapeuticsedgetherapeutics.com

Co-investorsBioBrit

Entasis Therapeutics

Antibacterials to treat serious drug-resistant bacterial infections.

Entasistxentasistx.com in 𝕏

Entasis Therapeutics is a biotechnology company developing and marketing therapies for critical care and infectious diseases, focusing on serious conditions with high unmet need.

BiotechHealthtech

Entellus MedicalJul 2017

HealthtechPlymouth, US

John K. Bakewell(Director)Brian E. Farley(Director)Shawn T McCormick(Director)David B. Milne(Director)Douglas Rohlen(Director)Stephen R. Paidosh(Executive Officer)

Entelosentelos.com

Sam Holtzman(Founder)in

Co-investorsBoulder Ventures

Firstaidshottherapyfirstaidshottherapy.com

Forty Seven Incfortyseveninc.com in 𝕏acquired by Gilead · Mar 2020

Forty Seven Inc was a clinical-stage immuno-oncology company developing antibody therapies targeting CD47, a "don't eat me" signal exploited by cancer cells, with lead candidate magrolimab.

BiotechHealthtechPalo Alto, US

Christopher Schaepe(Director)Dennis Henner(Director)Ravindra Majeti(Director)Eric Jensen(Executive Officer)Irving Weissman(Director)

BoardJeffrey Bird(Director)

Co-investorsBluebird Ventures Lightspeed Venture Partners

Galera Therapeuticsgaleratx.com in 𝕏

Galera Therapeutics is a biotechnology company developing antibody-based and other therapeutics.

BiotechHealthtechMedical DevicesMalvern, US

Mel Sorensen(Executive Officer, Director)Joel Sussman(Executive Officer)Jeffery L. Keene(Executive Officer)Dennis P. Riley(Executive Officer)Jon T. Holmlund(Executive Officer)Robert A. Beardsley(Executive Officer, Director)

Co-investorsNew Enterprise Associates (NEA)

Genitope

Gritstone Bio

BiotechEmeryville, US

Andrew Allen(Executive Officer, Director)Vassiliki Economides(Executive Officer)Matthew Hawryluk(Executive Officer)Shefali Agarwal(Director)Elaine Jones(Director)Naiyer A. Rizvi(Director)

Co-investorsFrazier Life Sciences REDMILE

Guavusguavus.comJun 2015

The site at this domain is a consumer guide to online casinos in Florida, publishing reviews, rankings, and explanations of gambling laws, bonuses, payment methods, and responsible play.

Media & EntertainmentSan Mateo, US

Anukool Lakhina(Executive Officer, Director)

BoardJose Suarez(Director)Amit Shah(Director)Brian Wilcove(Director)Andrew Fligel(Director)Michael LaJoie(Director)

Co-investorsTransLink Capital Artiman Ventures Goldman Sachs Intel Capital QuestMark Partners SingTel Innov8 Pte Ltd.

Gyroscopetxgyroscopetx.com in 𝕏

Co-investorsCambridge Innovation Capital

Healthcare North America Growth Stageartbio.com in 𝕏Jul 2025

ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue.

BiotechHealthtechMedical DevicesOslo, NO

Roy Larsen(Scientific Founder)Øyvind Bruland(Scientific Founder)Jonathan Freeman(Interim CEO)Margaret Yu(Chief Medical Officer)Philippe Dasse(Chief Technical Officer)Amra Demirovic(Chief Human Resources Officer)

Co-investorsB Capital Group B4 Capital F-Prime Capital Alexandria B Capital Qatar Investment Authority+1 more

HeartSpan Technologies

Histogenicshistogenics.com

HealthtechWaltham, US

Adam Gridley(Executive Officer, Director)Peter Greenleaf(Executive Officer, Director)

BoardJoshua Baltzell(Director)Kevin Rakin(Director)Garheng Kong, M.D., Ph.D.(Director)Garheng Kong, M.D., Ph.D(Director)

Co-investorsFOUNDATION MEDICAL PARTNERS Split Rock Partners

Humanigenhumanigen.com

Humanity Therapeutics

Hyperion Therapeutics

Addressing unmet needs in gastroenterology and hepatology.

BiotechBrisbane, US

Bo Jesper Hansen(Director)Christine Nash(Executive Officer)Natalie Holles(Executive Officer)Jake R. Nunn(Director)Bijan Salehizadeh(Director)Daniel G. Welch(Director)

Co-investorsBay City Capital

Hyperiontxhyperiontx.com

InCarda Therapeuticsincardatherapeutics.com in

Incardatherapeutics develops drug therapies for treating atrial fibrillation using synergistic combinations of anti-arrhythmic agents, with delivery platforms designed for both hospital and at-home settings.

BiotechDigital HealthMedical DevicesBrisbane, US

Rangachari Narasimhan(Executive Officer, Director)Grace Colon(Executive Officer, Director)Miller Samantha(Executive Officer)Carlos A. Schuler(Executive Officer, Director)John S. Patton(Executive Officer, Director)

BoardMcCarthy Reenie(Director)

Co-investorsAsset Management Company HealthCap Deerfield Management Company

Innocollinnocoll.com

Co-investorsFountain Healthcare Partners

Inozyme Pharmainozyme.com

BiotechBoston, US

Axel Bolte(Executive Officer, Director)inReinaldo Diaz(Director)Joseph Schlessinger(Executive Officer, Director)

BoardEdward Mathers(Director)Rob Hopfner(Director)Martin Edwards(Director)

Co-investorsLongitude Capital New Enterprise Associates (NEA)Sanofi Ventures Pivotal Life Sciences

Intellikineintellikine.com

InterMune NASDAQ: ITMN www.intermune.comintermune.com

daniel welchin

Co-investorsSanderling Ventures

Intrepidabiointrepidabio.com

Iterum Therapeuticsiterumtx.com

Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.

BiotechDigital HealthHealthtechMedical DevicesDublin, US

Michael W. Dunne(Executive Officer, Promoter)Corey N. Fishman(Executive Officer, Director, Promoter)Judith M. Matthews(Executive Officer, Promoter)Jeff Schaffnit(Executive Officer)

BoardBrenton K. Ahrens(Director)Ronald M. Hunt(Director)

Co-investorsBay City Capital Canaan Partners Frazier Life Sciences Sofinnova Venture Partners

Jounce Therapeutics

Kalyota

Karuna Therapeutics

PureTech Founded Entity that developed KarXT (Cobenfy) for schizophrenia and was acquired by Bristol Myers Squibb for $14 billion.

Co-investorsPureTech Health

Karunatxkarunatx.comAcquired

Karuna Therapeutics is a Boston neuroscience biopharma behind muscarinic drug KarXT, acquired by Bristol Myers Squibb in 2024.

Co-investorsARCH Venture Partners

Kiniksakiniksa.com in 𝕏

Kiniksa is a global biopharmaceutical company that discovers and develops novel therapies for patients with unmet medical needs, with a focus on cardiovascular diseases and related conditions.

BiotechMedical Devices

Kiromic BioPharma

Lifegen Biotechnologies

Mallinckrodtmallinckrodt.com inAcquired

Following a 2025 merger of Mallinckrodt and Endo, the combined business separated into two companies: Keenova Therapeutics, which develops treatments for rare, stigmatized, or unaddressed conditions across areas such as immunology, urology, hepatology, ophthalmology, orthopedics, and critical care; and Par Health, which produces generics, sterile injectables, and active pharmaceutical ingredients backed by a U.S.-based manufacturing network.

Advanced ManufacturingBiotechHealthtechMedical Devices

Co-investorsARCH Venture Partners Cross Creek Advisors Pfizer Venture Investments Signet Healthcare Partners

Mareamareatx.com in 𝕏

Co-investorsAlpha Wave Global venBio Partners

Marinus Pharmaceuticalsmarinuspharma.com

BiotechRadnor, US

Scott Braunstein, MD(Executive Officer, Director)Edward F. Smith(Executive Officer)Joe Hulihan, MD(Executive Officer)

BoardNicole Vitullo(Director)Enrique J. Carrazana, MD(Director)Michael R. Dougherty(Director)

Co-investorsAvoro Capital Advisors Bain Capital Life Sciences Canaan Partners Connecticut Innovations Domain Associates Flare Capital Partners +1 more

Medeor Therapeuticsmedeortherapeutics.com

Meru Therapeutics

Merusmerus.nl in

Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications.

BiotechMedical DevicesUtrecht, NL

Ton Logtenberg(Executive Officer, Director)Mark Throsby(Executive Officer)Hui Liu(Executive Officer)John Crowley(Executive Officer)L. Andres Sirulnik(Executive Officer)Lex Bakker(Executive Officer)

Co-investorsAvoro Capital Advisors Pfizer Venture Investments RA Capital

Metacel

Microbiome Therapeutics in

HealthtechNew Orleans, US

Mark Heiman(Executive Officer)Dale Pfost(Executive Officer, Director, Promoter)

BoardDon Marvin(Director)Richard Montgomery(Director)Ross Barrett(Director)John Elstrott(Director, Promoter)

Co-investorsBayern Kapital DCVC (Data Collective)FemHealth Ventures Pangaea Ventures

Misonix

Co-investors1315 Capital SV Health Investors

Mtemmtem.com

Molecular Templates, Inc. was a clinical-stage biopharmaceutical company formerly based in Austin, TX.

BiotechAustin, US

Co-investorsLongitude Capital Solasta Ventures

Naurexnaurex.com

Developed next-generation depression pharmaceuticals; acquired in 2015 for $560M upfront plus milestones.

BiotechEvanston, US

Joseph R. Moskal(Executive Officer)Amin Khan(Executive Officer)James Schulz(Executive Officer)Ronald M. Burch(Executive Officer)Norbert Riedel(Executive Officer, Director)Ashish Khanna(Executive Officer)

Co-investorsCota Capital EcoR1 Capital Latterell Venture Partners

Neon Therapeuticsneontherapeutics.com

BiotechCambridge, US

Richard Gaynor, M.D.(Executive Officer)Robert Ang, M.D.(Executive Officer)Yasir Al-Wakeel(Executive Officer)Eric Lander(Director)Hugh Dowd(Executive Officer, Director)

BoardCary Pfeffer, M.D.(Director)

Co-investorsNextech Invest Clal Biotechnology Industries Third Rock Ventures

Neos TherapeuticsMar 2014

BiotechGrand Prairie, US

Steven Lutz(VP Sales)Carolyn Sikes(VP Clinical Affairs)Russ McMahen(VP Research and Development)Margaret Cabano(VP Operations)Richard Eisenstadt(Chief Financial Officer and Secretary)Asif Mughal(VP Quality Assurance)

Neurana Pharmaceuticals

Developing a novel treatment for acute muscle spasms.

BiotechSan Diego, US

Kathleen D. Scott(Chief Financial Officer, Secretary and Treasurer)Judy Caron(Chief Operating Officer)David F. Hale(Chairman of the Board of Directors, Acting President and CEO)Brian Dorsey(Director)Daniel Becker(Director)Joshua Richardson(Director)

Co-investorsH.I.G. HealthBridge Partners Longitude Capital

Neuranapharmaneuranapharma.com

Nexigen Biopharma

Nextwavepharmanextwavepharma.comacquired by Tris Pharma

Medical DevicesNew Jersey, US

Co-investorsBay City Capital F-Prime Capital

Northsea Therapeuticsnorthseatherapeutics.com in

NorthSea Therapeutics is a late-stage clinical biotechnology company developing structurally engineered fatty acids (SEFAs) as oral treatments for metabolic, cholestatic, and fibrotic diseases.

BiotechHealthtech

Co-investorsNew Science Ventures venBio Partners Ysios Capital

Nucleonyx Pharmaceuticals

Nurix Therapeuticsnurixtx.com in 𝕏

Nurix Therapeutics develops targeted protein degradation medicines, including degrader-antibody conjugates (DACs), designed to eliminate disease-causing proteins using the cell's natural degradation machinery.

AI & Machine LearningBiotechDeep TechSan Francisco, US

Arthur T. Sands(Executive Officer, Director)Timothy Kutzkey(Executive Officer, Director)

BoardDavid Goeddel(Director)Mark Goldsmith(Director)

Co-investorsBain Capital Life Sciences EcoR1 Capital Foresite Capital The Column Group

ObsEvaobseva.com 𝕏

The page is a Vietnamese-language sports streaming site (90Phut TV / 90Phutr.tv, also called Vaoroi TV) offering free live football streaming links, match schedules, standings, results, news, and betting odds.

Media & EntertainmentSports TechHà Nội, VN

Co-investorsAisling Capital M Ventures New Enterprise Associates (NEA)Sofinnova Partners

Ocular Therapeutix Nasdoculocutx.com in 𝕏

Ocular is a clinical-stage biopharmaceutical company developing AXPAXLI (OTX-TKI), an investigational axitinib intravitreal hydrogel, aimed at reducing the treatment burden of retinal diseases.

BiotechHealthtechMedical DevicesBedford, US

W. James O'Shea(Director)Kevin Hanley(Executive Officer)Richard L. Lindstrom(Director)Michael Goldstein(Executive Officer)Amarpreet Sawhney(Director)Daniel Bollag(Executive Officer)

Co-investorsAscension Ventures SV Health Investors Top Corner Capital Agent Capital

Oncusp Therapeuticsoncusptx.com in

OnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages.

BiotechMedical DevicesNew York, US

Dr. Bing Yuan(Co-Founder, Chief Executive Officer)Dr. Eric Slosberg(Co-Founder, Chief Development Officer)Dr. Andy Fu(Co-Founder, Chief Business Officer)

Co-investorsOrbiMed Catalio Capital Management, LP F-Prime Capital Insight Partners NVIDIA

Ophthotechophthotech.comOct 2018

BiotechNew York, US

David Guyer(Executive Officer, Director)Glenn Sblendorio(Executive Officer, Director)Mike AtiehinDavid Redlick(Director)Keith Westby(Executive Officer)David Carroll(Executive Officer)

Co-investorsSV Health Investors Clarus SV Life Sciences

Orexigenorexigen.com

Orexigen Therapeuticscurraxpharma.com in

Currax Pharmaceuticals develops and markets a portfolio of therapies for chronic progressive diseases.

BiotechHealthtechLa Jolla, US

Preston Klassen(Executive Officer)Joseph Hagan(Executive Officer)Michael Narachi(Executive Officer, Director)Thomas Cannell(Executive Officer)

BoardEckard Weber(Director)Brian H. Dovey(Director)in

Co-investorsCross Creek Advisors New Enterprise Associates (NEA)Domain Associates Domain Partners

Perception Neuroscienceperceptionns.com

Perception Neuroscience is a clinical-stage biotech developing R-ketamine (PCN-101), a single-isomer glutamatergic modulator being studied as a rapid-acting antidepressant for patients with treatment-resistant depression.

BiotechDigital HealthHealthtechMental Health

PharmaSonicspharmasonics.com

Phocéa Pharma

Pionyr Immunotherapeuticspionyrtx.com in

HealthtechSan Francisco, US

Matthew F. Krummel, Ph.D.(Director)Steven P. James(Executive Officer, Director, Promoter)Leon Chen, Ph.D.(Director)Carol Gallagher(Director)Joshua Resnick, M.D.(Director)

BoardMichael Powell(Director)

Co-investorsMission Bay Capital Mission Biocapital New Enterprise Associates (NEA)OUP (Osage University Partners)Sofinnova Venture Partners

PregLempreglem.com

Co-investorsSofinnova Partners

Principia Biopharmaprincipiabio.com

BiotechSouth San Francisco, US

MARTIN BABLER(Executive Officer, Director)

BoardPETER THOMPSON(Director)SRINIVAS AKKARAJU(Director)MICHAEL DYBBS(Director)inSIMEON GEORGE(Director)LEWIS J. SHUSTER(Director)

Co-investorsAccess Biotechnology Mission Biocapital Mission Bay Capital New Leaf Venture Partners OrbiMed Samsara BioCapital

Prodigy Biotech

Progenics Pharmaceuticals

Co-investorsHEALTHCARE ROYALTY PARTNERS

Promediorpromedior.comFeb 2012

BiotechMalvern, US

Mark Lupher(Executive Officer)Dominick C. Colangelo(Executive Officer, Director)

BoardJames W. Broderick, M.D.(Director)Geert-Jan Mulder(Director)John Friedman(Director)Harold R. Werner(Director)

Co-investorsEaston Capital Easton Capital Investment Group Forbion

Proteostasis Therapeutics

Co-investorsF-Prime Capital New Enterprise Associates (NEA)

Rainierrxrainierrx.com

Raptor Pharmaceuticals

Reata Pharmaceuticalsacquired by Biogen

Pharmaceutical company acquired by Biogen

Co-investorsFrazier Life Sciences Kern Capital, LLC

Retinal Implant

RXSTATUS

Saegis Pharmaceuticals

Discovery and development of drugs to address behavioral disorders.

Sangamo Biotherapeutics

Sarcodesarcode.com

Seagen

Seattle Geneticsseattlegenetics.com in 𝕏acquired by Pfizer

BiotechHealthtechMedical DevicesNew York, US

Charles Pfizer

Sensei BiotherapeuticsFeb 2026

BiotechRockville, US

Kristian Humer(Director)Christopher Gerry(Executive Officer, Director)Anand Kiran Parikh(Executive Officer, Director)Josiah Craver(Executive Officer)

BoardBob Holmen(Director)Phillip B. Donenberg(Director)

Serica Technologies

Sophiris BIOsophirisbio.comAug 2019

BiotechLa Jolla, US

Allison E. Hulme(Executive Officer, Director)Randall E. Woods(Executive Officer, Director)Peter T. Slover(Executive Officer)Gerald T Proehl(Director)John E Geltosky(Director)Jim E. Heppell(Director)

Spark Therapeutics

One-time gene therapy products including a candidate for RPE65-related blindness.

BiotechPhiladelphia, US

Joseph W. La Barge(Executive Officer)Elliott Sigal(Director)Rogerio Vivaldi(Director)Arthur Dantchik(Director)Lars Ekman, M.D. Ph.D.(Director)Steven M. Altschuler(Director)

Sparktxsparktx.com in

Spark Therapeutics, now part of the Roche Group, focuses on delivering therapies to improve patient outcomes and create healthier communities.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsFountain Healthcare Partners

Sybios Corporation

Syros Pharmaceuticals

Co-investorsBain Capital Life Sciences

Tensysmedicaltensysmedical.com

Transgenomic

BiotechOmaha, US

Paul Kinnon(Executive Officer, Director)Leon F. Richards(Executive Officer)ANTONIUS P SCHUH(Director)CRAIG J TUTTLE(DIRECTOR, PRESIDENT AND CEO)CHAD M RICHARDS(CHIEF COMMERCIAL OFFICER)BRETT L FREVERT(CFO)

Translate Bioacquired by Sanofi

RNA therapeutics; NASDAQ TBIO, acquired by Sanofi.

Co-investorsM Ventures MRL Ventures Fund

Triusrxtriusrx.com

TSROtesarobio.com

Co-investorsKleiner Perkins Ridgeback Capital

Browse all 211 investments with full details →

▶11 more tracked companies

Velosbio VeratxVersartisVesalius TherapeuticsVicepttxVion PharmaceuticalsVisen PharmaceuticalsXylocorXyloCor TherapeuticsYmabs ZS Pharma

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 28

IPOs and acquisitions across the tracked portfolio

BioAge LabsNASDAQ: BIOANextCureNASDAQ: NXTCSeaport TherapeuticsNASDAQ: SPTXVera TherapeuticsNASDAQ: VERAAclaris TherapeuticsNASDAQ: ACRSAnavex Life SciencesNASDAQ: AVXLaTYR PHARMANASDAQ: ATYRBolt BiotherapeuticsNASDAQ: BOLTCoherus BiosciencesNASDAQ: CHRSEditas MedicineNASDAQ: EDITEnanta PharmaceuticalsNASDAQ: ENTAKiniksa PharmaceuticalsNASDAQ: KNSALigand PharmaceuticalsNASDAQ: LGNDNateraNASDAQ: NTRANucanaNASDAQ: NCNAProtalix BioTherapeuticsNYSE: PLXProthenaNASDAQ: PRTARapport TherapeuticsNASDAQ: RAPPSeres TherapeuticsNASDAQ: MCRBSyndax PharmaceuticalsNASDAQ: SNDXSynlogicOTC: SYBXAerovatetxacq. by Jade BiosciencesAlimerasciencesacq. by ANI PharmaceuticalsForty Seven Incacq. by GileadNextwavepharmaacq. by Tris PharmaReata Pharmaceuticalsacq. by BiogenSeattle Geneticsacq. by PfizerTranslate Bioacq. by Sanofi

Portfolio news

latest coverage across their companies

Investigation launched into Arcus Biosciences o... | Pluang

Arcus Biosciences · pluang.com · Aug 19, 2026

Nurix Therapeutics (NRIX) Starts Phase 3 And Lands Sanofi Milestone, Is The Valuation About Right? - Simply Wall St News

Nurix Therapeutics · simplywall.st · Aug 18, 2026

ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $47.00 - Ticker Report

Arrivent · tickerreport.com · Aug 17, 2026

Renaissance Technologies LLC Acquires 251,378 Shares of Anavex Life Sciences Corp. $AVXL - Markets Daily

Anavex Life Sciences · themarketsdaily.com · Aug 16, 2026

Handelsbanken Fonder AB Raises Stake in Ligand Pharmaceuticals Incorporated $LGND - Defense World

Ligand Pharmaceuticals · defenseworld.net · Aug 16, 2026

Syndax (SNDX) Q2 2026 Earnings Call Transcript - AOL

Syndax Pharmaceuticals · aol.com · Aug 12, 2026

Claris Bio raises $118M to advance first-ever LSCD therapy

Claris Bio · glance.eyesoneyecare.com · Aug 3, 2026

Claris Biotherapeutics Raises $118M in Series B Funding

Claris Biotherapeutics · finsmes.com · Aug 3, 2026

Fund performance · per public LP disclosures · 4

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
Sofinnova Venture Partners IXLPs: California State Teachers' Retirement System	2014	—	7.2%	1.47x	1.01x
SOFINNOVA VENTURE PARTNERS VIII LPLPs: Oregon Public Employees Retirement System, California State Teachers' Retirement System, University of Texas Investment Management Company	2011	—	21.9%	1.66x	1.66x
Sofinnova Venture Partners VIILPs: Oregon Public Employees Retirement System	2007	—	14.7%	1.71x	1.71x
Sofinnova Venture Partners VILPs: Orange County Employees Retirement System	1999	—	-19.8%	0.10x	0.15x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Public market activity · per SEC filings

what is this? ⓘ

ArriVent BioPharma, Inc.SC 13G

Disclosed stake · filed Nov 2024

view filing ↗

BioAge Labs, Inc.SC 13D

Disclosed stake · filed Sep 2024

view filing ↗

Rapport Therapeutics, Inc.SC 13D

Disclosed stake · filed Jun 2024

view filing ↗

From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.

Frequently asked questions

How many investments has Sofinnova Ventures made?: Sofinnova Ventures has 178 tracked investments, 11 of which have exited via acquisition or IPO, including 7 dated in the last 24 months.
What stage does Sofinnova Ventures invest at?: Sofinnova Ventures invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is Sofinnova Ventures's typical check size?: Sofinnova Ventures typically writes checks of $100K – $15M.
What sectors does Sofinnova Ventures focus on?: Sofinnova Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Sofinnova Ventures located?: Sofinnova Ventures is headquartered in Menlo Park, US.
Does Sofinnova Ventures lead rounds?: Sofinnova Ventures typically participates in rounds rather than leading them.
Who does Sofinnova Ventures co-invest with?: Sofinnova Ventures most often shares deals with Foresite Capital, New Enterprise Associates (NEA), RA Capital, among 107 tracked co-investors.

Images

Co-investors · 30

New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

Both backed · 12

Synlogic Akouos Amplyx Pharmaceuticals Avenzo Galera Therapeutics Inozyme Pharma ObsEva Orexigen Therapeutics Pionyr ImmunotherapeuticsAlimerasciencesCatalystbiosciencesProteostasis Therapeutics

$200K – $40M

OrbiMed

OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 11

BioAge Labs NextCure Synlogic Aerpio Therapeutics Arrivent Avenzo Civitas Therapeutics Oncusp Therapeutics Principia Biopharma Star Therapeutics Velosbio

$1M – $75M

F-Prime Capital

F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.

Both backed · 9

Aclaris Therapeutics Coherus Biosciences Checkmate Pharmaceuticals Oncusp Therapeutics RarecyteApellisHealthcare North America Growth StageNextwavepharmaProteostasis Therapeutics

$3M – $10M

venBio Partners

venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.

Both backed · 8

Syndax Pharmaceuticals Aeovian Pharmaceuticals Axonis Therapeutics Northsea Therapeutics Rayze BioApellisMareaMarea Therapeutics, Inc.

Canaan Partners

Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.

Both backed · 5

NextCure Antiva Biosciences Civitas Therapeutics Iterum Therapeutics Marinus Pharmaceuticals

$500K – $20M

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.

Both backed · 5

Rapport Therapeutics Seaport Therapeutics City Therapeutics Karunatx Mallinckrodt

$50K – $250M

Forbion

Forbion is a global venture capital firm focused on advancing biotech innovations and sustainable solutions aimed at improving human and planetary health.

Both backed · 4

Coultreon Expeditiontx PromediorGyroscope Therapeutics Ltd

Kleiner Perkins

Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.

Both backed · 3

Vera TherapeuticsVeratxTSRO

$500K – $15M

Sofinnova Partners

Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.

Both backed · 3

CinCor Pharma ObsEvaPregLem

$540K – $27M

Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.

Both backed · 3

Expeditiontx Inozyme Pharma Star Therapeutics

$5M

Pivotal Life Sciences

Pivotal Life Sciences is an investment platform focused on funding innovative companies developing therapeutic products and technologies aimed at major unmet medical needs.

Both backed · 3

Bolt Biotherapeutics Akouos Inozyme Pharma

SR One Capital Management

SR One is a biotechnology-focused venture capital firm that partners with founders to develop innovative science into new medicines.

Both backed · 2

AvenzoElektrofi, Inc.

▶18 more co-investors

Third Rock Ventures Vida Ventures Andreessen Horowitz General Catalyst GV (Google Ventures)B Capital Group Cambridge Innovation Capital Abingworth VantagePoint Capital Partners Westlake Village BioPartners BoxOne Ventures Sequoia Capital Entrepreneur First Johnson & Johnson Innovation – JJDC Morgenthaler Novartis Venture Fund Frazier Healthcare Partners ACORN BIOVENTURES

Firms observed investing alongside Sofinnova Ventures, from public investor directories. Shared companies are the overlap with Sofinnova Ventures's recorded portfolio.

Similar investors

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Capricorn Venture Partners

Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.

$270K – $10.8M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Eight Roads Ventures

Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.

$5M – $30M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

$250K – $50M

Featured in lists

Investors & VC Firms in North America Investors & VC Firms in United States Seed Investors & VC Firms Series A Investors & VC Firms Seed Investors & VC Firms in North America Seed Investors & VC Firms in United States Growth Investors & VC Firms Series A Investors & VC Firms in North America Series B Investors & VC Firms Series A Investors & VC Firms in United States Investors & VC Firms in Global Healthtech Investors & VC Firms

Website & social

sofinnova.com

/sofinnova-ventures @SofinnovaUS watch video

signal ↗crunchbase ↗

As published on the firm's website.

Contact

Menlo Park3000 Sand Hill Rd
Building 3-Suite 150
Menlo Park, CA 94025
United States

BostonOne Marina Park Drive
Suite 300
Boston, MA 02210
United States

New York27 West 24th Street
Suite 302
New York, NY 10010
United States

Emailinfo@sofinnova.com

Phone(650) 681-8420

Fax(650) 322-2037

FoxScore

Combines investment activity, responsiveness, founder feedback, closing rate and follow-through reported by founders on Fox. Sign up to see it.

Your history

Sofinnova Ventures isn't in your CRM yet.

+ Add to CRM

Track outreach, deck opens, and next steps across your whole raise.

✨ Smart outreach

✨ Best warm path

Funds

SOFINNOVA VENTURE PARTNERS XII, L.P.vintage 2024 · 75 LPs · 506(c)$20.5MAUM

SOFINNOVA VENTURE PARTNERS XI, L.P.vintage 2021 · 52 LPs · 506(b)$308.7MAUM

SOFINNOVA BIOEQUITIES ENHANCED MASTER FUND, LPMar 2026 · 28 LPs$1.2BAUM

SOFINNOVA VENTURE PARTNERS X, L.P.Mar 2026 · 60 LPs$259.3MAUM

SOFINNOVA BIOEQUITIES MASTER FUND, LTD.Mar 2026 · 50 LPs$121.4MAUM

SOFINNOVA SYNERGY MASTER FUND, LPMar 2026

+1 more funds

Source: SEC Form ADV Schedule D and EDGAR Form D filings. AUM is gross asset value as reported by the adviser.

Latest on 𝕏

Sofinnova Investments @sofinnovaus

This year, Sofinnova celebrates 50 years of partnering with visionary entrepreneurs to advance breakthrough science and help bring innovative therapies to patients. We're proud of what we've accomplished together, and we're even more excited about what's ahead as scientific https://t.co/iikelHx7Qd

Jul 30, 2026 · ♥ 1 · ⇄ 1

Sofinnova Investments @sofinnovaus

Congratulations to the Claris Biotherapeutics team on today’s launch and successful $118 million Series B financing. We at @SofinnovaUS are excited to support Claris alongside an outstanding investor syndicate to advance CSB-001 (oremepermin alfa ophthalmic solution) in limbal https://t.co/93RH2zOV4S

Jul 28, 2026

Sofinnova Investments @sofinnovaus

@SofinnovaUS Executive Partner @MahaRadhakrish2 speaks with @biospace on AI Data Becomes Sticking Point in Biopharma Dealmaking https://t.co/wfbGyIglce https://t.co/NVk3oeRbo6

Jul 24, 2026